We set out to improve tuberculosis treatment, where patients often struggled with side effects and low treatment adherence. To change this, we developed Risorine, a first-of-its-kind combination of rifampicin, isoniazid, and piperine, a natural bio-enhancer from black pepper. Piperine increased rifampicin’s absorption, allowing us to lower the dose from 450 mg to 200 mg without reducing effectiveness.

This made the treatment gentler, safer, and easier to continue. Multicentre clinical studies confirmed better cure rates and improved safety, strengthening the fight against tuberculosis.

We saw how cardiovascular patients often struggled to keep up with multiple medications. To ease this burden, we created Polycap, a five-in-one fixed-dose combination of Simvastatin, Ramipril, Atenolol, Hydrochlorothiazide, and Aspirin. By bringing everything into a single pill, we improved adherence and simplified daily treatment.

Clinical studies showed meaningful reductions in cardiovascular risk factors, strengthening both prevention and long-term outcomes.

We saw the struggle behind the statistics, where a demanding five-dose rabies regimen often stood in the way of timely care, especially in underserved communities. To overcome this, we introduced Thrabis, a three-dose rabies vaccine given intramuscularly within one week.

By shortening the treatment course, we made vaccination more accessible, improved compliance, and strengthened protection against rabies, particularly in resource-limited settings.

We witnessed how sepsis continued to claim lives despite antibiotic treatment, leaving clinicians with limited options. To respond to this critical need, we developed Sepsivac, an immunomodulatory drug derived from heat-killed Mycobacterium w. By regulating the body’s immune response, Sepsivac improved survival in patients with gram-negative sepsis and demonstrated efficacy in critically ill COVID-19 patients.

This breakthrough marked our role as pioneers in immunotherapy for life-threatening infections.

We set out to strengthen protection against seasonal influenza, a disease that continues to impact millions every year. Conventional egg-based vaccines had their limits, including variable efficacy and allergy concerns. In response, we developed Cadiflu Tetra, India’s first VLP-based quadrivalent influenza vaccine, using WHO-recommended strains to protect against seasonal influenza (flu)—an acute viral respiratory tract infection caused by the influenza virus.

Powered by advanced Virus-Like Particle (VLP) technology, it delivers a strong immune response with an excellent safety profile, while remaining economical and accessible. Cadiflu Tetra is indicated for active immunisation in adults and children from 6 months of age (especially those with respiratory illness or other NCDs), healthcare professionals, and immunocompromised individuals. Protection is achieved with a single 0.5 ml intramuscular injection, making Cadiflu Tetra a convenient and innovative solution for seasonal flu prevention in India.